ZEUS Scientific Now Offers a Comprehensive Menu of SARS-CoV-2 Antibody Test Systems
ZEUS Scientific Now Offers a Comprehensive Menu of SARS-CoV-2 Antibody Test Systems
ZEUS Scientific immediately reacted to the COVID-19 pandemic by lending over 40 years of our expertise of in vitro diagnostic (IVD) development to provide multiple tools to aid in the fight against the SARS-CoV-2 virus. ZEUS recognizes in the race to respond to COVID-19 patient results cannot be compromised. From the beginning we understood we needed to carefully select and optimize the target SARS-CoV-2 antigens from which we would build our assays. Each ZEUS assay utilizes a dual antigen combination of recombinant Spike Protein (S1) and recombinant Nucleoprotein (N-protein) for optimal performance. We now offer 3 separate SARS-CoV-2 antibody test systems across two methodologies testing for IgG, IgG/IgM and IgG/IgM/IgA which can be utilized individually or combined to implement an orthogonal testing algorithm for positive results to increase positive predictive value, all from the same manufacturer. We realize in the battle against COVID-19 one size does not fit all and are able to accommodate laboratories looking for rapid antibody testing as well as automated antibody testing.
ZEUS now offers flexibility within our ELISA assays of simultaneously testing for SARS-CoV-2 IgG, IgM and IgA antibodies or testing for IgG only. Some laboratories may be targeting the IgG response which typically takes longer to develop but may offer protection from future infection while others may be looking for any and all patient anti-SARS-CoV-2 antibodies regardless of class. Our tests are designed to be adaptable to a wide range of applications and throughput needs. Additionally, ZEUS has paved the road by validating our ELISA tests on Dynex’s ELISA instruments (DS2®, DSX®, Agility™).
Proving Consistency Across our Menu
As the number of available SARS-CoV-2 antibody tests continues to increase, it is now even more difficult to compare their performance. Each new test is released by testing unique specimens leaving it to the laboratory to decide how the performance of the new test compares to another test. ZEUS has recently completed extensive performance testing of all 3 of our devices using the same 3 cohorts (total n=365) of clinically characterized patient samples. The study data allows for direct comparison of our entire menu of SARS-CoV-2 antibody tests and provides confidence to the laboratory in each of our 3 tests. A detailed data analysis will be released shortly on our website. Until then we can share an overall correlation of over 97% across all 3 assays. ZEUS has been developing IVD assays for over 40 years and understands there is a patient behind every result and all results matter regardless of the method or test. ZEUS is ready to show consistency and accuracy in SARS-CoV-2 antibody testing.
Test with Confidence. Test with ZEUS. |
For over 40 years, laboratories have trusted ZEUS Scientific to provide high quality in vitro diagnostic immunoassays for numerous infectious diseases. With over 125 FDA cleared assays in our menu, our company has a proven skillset of developing, manufacturing and distributing a family of products to aid in the diagnosis of complex infectious agents including a variety of known viral pathogens. We have concentrated our focus to the COVID-19 pandemic and the SARS-CoV-2 virus.
For more information please visit our website or contact our sales team. To order, call 1.800.286.2111 or email orders@zeusscientific.com and ask for the following Product Codes:
- ZEUS Rapid SARS-CoV-2 IgM/IgG: POC7801 (or order online!)
- ZEUS ELISA SARS-CoV-2 IgG: SM9Z7901G (or order online!)
- ZEUS ELISA SARS-CoV-2 Total Antibody: SM9Z7901 (or order online!)
Sincerely,
The ZEUS Scientific Family
Back Share